Avmapki Fakzynja Co-Pack: Dosage Form, Projected Sales, NCE-1 Date | Avutometinib And Defactinib

Avmapki Fakzynja Co-Pack

Avmapki Fakzynja combines two oral kinase inhibitors for adults with KRAS‑mutated recurrent low‑grade serous ovarian cancer after prior systemic therapy. It targets both MEK and FAK pathways to help control tumor growth in patients with limited treatment options.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Avutometinib And Defactinib
Innovator :

VERASTEM INC
Approval Date :

08-May-25
NCE-1 Date :

08-May-29
NCE Date :

08-May-30
Dosage Form :

Oral Capsule And Tablet
Strength :

EQ 0.8MG BASE; EQ 200MG BASE
Therapeutic Category :

Anticancer
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

31
2026 :

92
2027 :

150
2028 :

268
2029 :

405
2030 :

540
2031 :

676

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Avmapki Fakzynja Co-Pack

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?